消除乙肝病毒母婴传播的进展——美洲区域,2012—2022年
泛美卫生组织消除母婴传播策略要求乙肝疫苗出生剂次和3剂次覆盖率均≥95%、孕妇乙肝表面抗原检测率≥80%并对暴露新生儿提供免疫球蛋白。2012年全部51个国家提供3剂次疫苗,2021年34个(67%)提供出生剂次;数学模型估计14个(28%)国家及区域层面儿童乙肝表面抗原血清流行率≤0.1%。
要点
- 2021年34个(67%)美洲国家全国提供乙肝疫苗出生剂次。
- 2021和2022两年间仅3个(6%)国家同时达到出生剂次和3剂次95%覆盖目标。
- 2022年41个有2012年可比数据的国家中15个(37%)3剂次覆盖率下降≥10个百分点。
核心结论
- 3剂次覆盖率下降及17国常规免疫规划未纳入出生剂次,威胁泛美卫生组织消除乙肝病毒母婴传播的进展。
- 需努力引入出生剂次并维持高3剂次和出生剂次覆盖率。
- 14个(28%)国家及区域层面数学模型估计儿童乙肝表面抗原血清流行率≤0.1%;3个(6%)国家同时达到两剂次95%覆盖目标,其中2个可能已达到消除母婴传播标准。
研究设计与样本
- 基于世界卫生组织美洲区域51个国家和地区2012—2022年乙肝疫苗接种覆盖率及乙肝表面抗原血清流行率数据的进展分析,采用数学模型估计儿童血清流行率。
主要发现
- 2012年全部51个国家全国提供乙肝疫苗3剂次,2021年34个(67%)全国提供出生剂次。
- 2021和2022两年间3个(6%)国家同时达到出生剂次和3剂次95%覆盖目标,其中2个可能已达到消除母婴传播标准。
- 2022年41个有2012年可比数据的国家中15个(37%)3剂次覆盖率下降≥10个百分点。
- 数学模型估计14个(28%)国家及区域层面儿童乙肝表面抗原血清流行率≤0.1%。
- 17个国家常规免疫规划未纳入乙肝疫苗出生剂次。
关键数值与推荐
- 泛美卫生组织消除母婴传播策略目标:儿童乙肝表面抗原血清流行率≤0.1%。
- 过程指标:乙肝疫苗出生剂次和3剂次覆盖率均≥95%;孕妇乙肝表面抗原检测率≥80%并对暴露新生儿提供乙肝免疫球蛋白。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In 2022, an estimated 5 million persons in the World Health Organization Region of the Americas (AMR) were living with chronic hepatitis B virus (HBV) infection, the leading cause of hepatocellular carcinoma and cirrhosis worldwide. Most chronic infections are acquired through mother-to-child transmission (MTCT) or horizontal transmission during childhood and are preventable with hepatitis B vaccination, including a birth dose (HepB-BD), followed by 2-3 additional doses (HepB3) in infancy. The Pan American Health Organization (PAHO) Elimination of MTCT of HBV infection strategy is intended to reduce chronic HBV infection (measured by hepatitis B surface antigen [HBsAg] seroprevalence) to ≤0.1% among children by achieving 1) ≥95% coverage with HepB-BD and HepB3; and 2) ≥80% of pregnant women received testing for HBsAg, and provision of hepatitis B immunoglobulin to HBV-exposed neonates. By 2012, all 51 AMR countries and territories (countries) provided HepB3 nationwide, and by 2021, 34 (67%) provided HepB-BD nationwide. Mathematical models estimate that HBsAg seroprevalence in children is ≤0.1% in 14 (28%) of 51 countries and at the regional level. Three (6%) of 51 countries met the 95% coverage targets for both HepB3 and HepB-BD during both 2021 and 2022. Of these, two have likely met criteria for the elimination of MTCT of HBV infection. However, in 2022, HepB3 coverage had declined by ≥10 percentage points in 15 (37%) of 41 countries with 2012 coverage data for comparison. These declines in HepB3 coverage, as well as the absence of HepB-BD in the routine immunization schedules in 17 countries, threaten PAHO's progress toward the elimination of MTCT of HBV infection. Efforts to introduce HepB-BD and maintain high HepB3 and HepB-BD coverage are needed.
引用
- Alleman MM, Sereno LS, Whittembury A, et al. Progress Toward Elimination of Mother-to-Child Transmission of Hepatitis B Virus - Region of the Americas, 2012-2022. MMWR Morb Mortal Wkly Rep. 2024. PMID: 39052532. doi:10.15585/mmwr.mm7329a3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。